Indian Journal of Medical and Paediatric Oncology

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 41  |  Issue : 5  |  Page : 634--639

Continuing cancer treatment in a “COVID HOTSPOT” in India: Are we overestimating the risks?


Amit Surendra Parasnis, Dhananjay S Kelkar, Bhagyashree Suparn Khaladkar, Utkrant A Kurlekar, Chetan D Deshmukh, Sonali Pingle, Sachin S Hingmire, Padmaj S Kulkarni, Shailesh S Shende, Girish K Phadke, Mahesh B Sambhus, Sameer R Melinkeri, Shailesh A Kanvinde 
 Department of Oncosurgery, Medical Oncology and Radiation Oncology, Deenanath Mangeshkar Hospital and Research Centre, Erandwane, Pune, Maharashtra, India

Correspondence Address:
Dr. Amit Surendra Parasnis
Department of Oncosurgery, Medical Oncology and Radiation Oncology, Deenanath Mangeshkar Hospital and Research Centre, Erandwane, Off Karve Road, Pune - 411 004, Maharashtra
India

Context: We describe the treatment of cancer patients carried out in a Government of India-designated, dedicated coronavirus disease (COVID) hospital (DCH) in a COVID hotspot in India. Aims: The aim was to study the change and delay in the management of cancer patients during the pandemic and its complications. Settings and Design: This was an observational cohort study conducted at a tertiary care center, which was also a DCH. Subjects and Methods: Cancer patients receiving cancer surgery, chemotherapy, and radiotherapy in our DCH, during the lockdown, were studied. Results: A total of 864 patients received treatment for cancer in our hospital during the period of March 20, 2020 – May 31, 2020. There were no COVID-related complications. The treatment of 109/864 patients (12.61%) was delayed due to the pandemic and lockdown situation and the treatment plan was changed for 84/864 (9.72%) patients. There were 21 deaths in these 864 patients (2.43%), but only two deaths were COVID related. Symptomatic patients were tested for COVID, and 3/864 patients (0.34%) were detected to be COVID positive. Conclusions: We successfully delivered cancer treatment to patients in our DCH. The percentage of adverse effects, symptomatic COVID infection, and related mortality has been very low in our study. Cancer care can be continued with due diligence even during this pandemic.


How to cite this article:
Parasnis AS, Kelkar DS, Khaladkar BS, Kurlekar UA, Deshmukh CD, Pingle S, Hingmire SS, Kulkarni PS, Shende SS, Phadke GK, Sambhus MB, Melinkeri SR, Kanvinde SA. Continuing cancer treatment in a “COVID HOTSPOT” in India: Are we overestimating the risks?.Indian J Med Paediatr Oncol 2020;41:634-639


How to cite this URL:
Parasnis AS, Kelkar DS, Khaladkar BS, Kurlekar UA, Deshmukh CD, Pingle S, Hingmire SS, Kulkarni PS, Shende SS, Phadke GK, Sambhus MB, Melinkeri SR, Kanvinde SA. Continuing cancer treatment in a “COVID HOTSPOT” in India: Are we overestimating the risks?. Indian J Med Paediatr Oncol [serial online] 2020 [cited 2020 Dec 4 ];41:634-639
Available from: https://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=5;spage=634;epage=639;aulast=Parasnis;type=0